Beneficial effect in cardiovascular diseases and inflammation. Inhibits PGE2 formation from arachidonic acid in 3T3 fibroblats.
Product Details
| Alternative Name: | Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic acid (20:5, n-3), Icosapent |
| |
| Formula: | C20H30O2 |
| |
| MW: | 302.5 |
| |
| CAS: | 10417-94-4 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | Colorless oil. |
| |
| Solubility: | Soluble in 100% ethanol. |
| |
| Shipping: | Dry Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -20°C. After opening, store under an inert atmosphere (e.g. N2 or argon) at -80°C. Stock solutions are stable for up to 2 months at -80°C under an inert atmosphere. |
| |
| Handling: | Protect from air. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Differential effects of n-6 and n-3 polyunsaturated fatty acids on cell growth and early gene expression in Swiss 3T3 fibroblasts: U. Danesch, et al.; J. Cell. Physiol.
168, 618 (1996),
Abstract;
Eicosapentaenoic acid: its relevance in atherosclerosis and coronary artery disease: J. Mehta, et al.; Am. J. Cardiol.
59, 155 (1987),
Abstract;
Eicosapentaenoic acid as a modulator of inflammation. Effect on prostaglandin and leukotriene synthesis: T. Terano, et al.; Biochem. Pharmacol.
35, 779 (1986),
Abstract;
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function: T.H. Lee, et al.; N. Engl. J. Med.
312, 1217 (1985),
Abstract;
